CDEK by Data4ThePeople

Sign in Sign up

← All organizations

Asklepios BIoPharmaceutical

For profitWebsite ↗

Also known as: Actus Therapeutics, Inc. | AskBio Inc | Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio)

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 2

First clinical trial

Last known activity

May 1, 2026

Acquired by Bayer on Oct 26, 2020

Timeline

2000s

Jun 1, 2003
Asklepios BIoPharmaceutical— Founded

2020s

Oct 26, 2020
Bayer— Acquired By

Drugs by trial phase (5 distinct, 5 trials)

Phase 2 (5 own, 0 via acquisition)

Indications

Studied for

Glycogen Storage Disease Type II

Recent trials (5)

NCT07215403Lead sponsorPhase 2May 1, 2026
NCT07282847Lead sponsorPhase 1/Phase 2Dec 31, 2025
NCT06285643Lead sponsorPhase 2Jun 11, 2024
NCT05541627Lead sponsorPhase 1/Phase 2Oct 12, 2022
NCT03533673Lead sponsorPhase 1/Phase 2Oct 31, 2018

Details

Founded: Chapel Hill, NC, US Jun 1, 2003
Last known activity: May 1, 2026